Skip to main content

Drug Interactions between eszopiclone and Lusedra

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

eszopiclone fospropofol

Applies to: eszopiclone and Lusedra (fospropofol)

MONITOR: Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.

MANAGEMENT: Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly. Supportive therapy should be provided if needed.

References (10)
  1. McClune S, McKay AC, Wright PM, et al. (1992) "Synergistic interaction between midazolam and propofol." Br J Anaesth, 69, p. 240-5
  2. Gill SS, Wright EM, Reilly CS (1990) "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth, 65, p. 760-5
  3. (2001) "Product Information. Diprivan (propofol)." Astra-Zeneca Pharmaceuticals
  4. Pavlin DJ, Coda B, Shen DD, et al. (1996) "Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers." Anesthesiology, 84, p. 23-37
  5. Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A (1999) "Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study." Clin Pharmacol Ther, 66, p. 110-7
  6. (2008) "Product Information. Lusedra (fospropofol)." Eisai Inc
  7. (2024) "Product Information. propOFol Lipuro (B Braun) (propOFol)." B Braun Australia Pty Ltd, 3
  8. (2023) "Product Information. Diprivan (propofol)." Aspen Pharmacare Canada Inc
  9. (2024) "Product Information. Propofol (Lipuro) (propofol)." B.Braun Medical Ltd
  10. (2024) "Product Information. Propofol (propofol)." Hospira Inc

Drug and food interactions

Moderate

eszopiclone food

Applies to: eszopiclone

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

ADJUST DOSING INTERVAL: Administration of eszopiclone (the S-enantiomer of zopiclone) with or immediately after a high-fat/heavy meal may delay the onset of hypnotic effects. In healthy adults, administration of a 3 mg dose of eszopiclone after a high-fat meal decreased the mean peak plasma drug concentration (Cmax) by 21% and delayed the time to reach peak plasma drug concentration (Tmax) by approximately 1 hour. Theoretically, this interaction should also affect racemic zopiclone.

MANAGEMENT: Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol. For faster sleep onset, it may be advisable to not administer eszopiclone and zopiclone with or immediately after a high-fat/heavy meal.

References (2)
  1. (2004) "Product Information. Lunesta (eszopiclone)." Sepracor Inc
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer